Feb 6 (Reuters) - Bristol-Myers Squibb Co BMY.N:
Q4 ADJUSTED EPS $1.67 VERSUS IBES ESTIMATE $1.46
Q4 REVENUE $12.34 BILLION VERSUS IBES ESTIMATE $11.57 BILLION
OUTLOOK 2025 ADJUSTED EPS $6.55 TO $6.85 VERSUS IBES ESTIMATE $6.92
EXPANDS STRATEGIC PRODUCTIVITY INITIATIVE TO DELIVER ABOUT $2 BILLION IN ADDITIONAL COST SAVINGS BY2027 END
OUTLOOK 2025 REVENUES OF ABOUT $45.5 BILLION VERSUS IBES ESTIMATE $47.36 BILLION
((Reuters.Briefs@thomsonreuters.com;;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.